Documentos relacionados

1. Identification of cough-variant asthma phenotypes based on clinical and pathophysiologic data.
2. Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients.
3. Airway autoimmunity, asthma exacerbations, and response to biologics.
4. Real-life experience after 3 months with tezepelumab before marketing approval.
5. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.
6. Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting.
7. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
8. "Patient remodeling" as a consequence of uncontrolled and prolonged OCS use in severe asthma: how biologic therapy can reverse a dangerous trend.
9. Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments.
10. Remission in asthma.